MX338513B - Acidos grasos de longitud de cadena mediana y gliceridos como agentes de nefroprotección. - Google Patents
Acidos grasos de longitud de cadena mediana y gliceridos como agentes de nefroprotección.Info
- Publication number
- MX338513B MX338513B MX2010004856A MX2010004856A MX338513B MX 338513 B MX338513 B MX 338513B MX 2010004856 A MX2010004856 A MX 2010004856A MX 2010004856 A MX2010004856 A MX 2010004856A MX 338513 B MX338513 B MX 338513B
- Authority
- MX
- Mexico
- Prior art keywords
- nephroprotection
- agents
- medium
- fatty acids
- chain length
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se describe el uso de ácidos grasos de longitud de cadena mediana tales como ácido cáprico, ácido caprílico o ácido láurico y sus sales o mono- o di- o triglicéridos como agentes de nefroprotección para protegerlos contra la progresión de insuficiencia renal en enfermedades crónicas del riñón. Esto incluye el tratamiento de enfermedades del riñón asociadas con nefrectomía, fibrosis renal, esclerosis glomerular y enfermedad renal de etapa terminal. También incluye la protección del riñón contra el agente citotóxico usado en la quimioterapia o enfermedades autoinmunes o trasplante. Además incluye el tratamiento de la progresión de la insuficiencia renal asociada con la hipertensión, infarto, tumor, diabetes mellitus, autoinmunidad o inflamación.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US98509407P | 2007-11-02 | 2007-11-02 | |
PCT/CA2008/001930 WO2009055933A1 (en) | 2007-11-02 | 2008-11-03 | Medium-chain length fatty acids and glycerides as nephroprotection agents |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2010004856A MX2010004856A (es) | 2010-06-30 |
MX338513B true MX338513B (es) | 2016-04-20 |
Family
ID=40590499
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2010004856A MX338513B (es) | 2007-11-02 | 2008-11-03 | Acidos grasos de longitud de cadena mediana y gliceridos como agentes de nefroprotección. |
Country Status (19)
Country | Link |
---|---|
US (1) | US9532962B2 (es) |
EP (1) | EP2299998B1 (es) |
JP (1) | JP5575655B2 (es) |
KR (1) | KR101601987B1 (es) |
CN (1) | CN101878028A (es) |
AU (1) | AU2008318196B2 (es) |
BR (1) | BRPI0818310A8 (es) |
CA (1) | CA2704286C (es) |
DK (1) | DK2299998T3 (es) |
ES (1) | ES2664594T3 (es) |
IL (1) | IL205362A (es) |
MX (1) | MX338513B (es) |
MY (1) | MY151439A (es) |
NO (1) | NO2299998T3 (es) |
NZ (1) | NZ584981A (es) |
PT (1) | PT2299998T (es) |
RU (1) | RU2519215C2 (es) |
WO (1) | WO2009055933A1 (es) |
ZA (1) | ZA201003030B (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT2427416E (pt) | 2009-05-04 | 2016-06-15 | Prometic Pharma Smt Ltd | Compostos aromáticos substituídos e seus usos farmacêuticos |
JP5706142B2 (ja) * | 2010-04-28 | 2015-04-22 | 株式会社ファンケル | フユボダイジュ花のエタノール抽出物を有効成分とする血中グルコース低下剤、内臓脂肪蓄積抑制剤、tg低下剤、糞中脂肪排泄促進剤 |
MY162420A (en) | 2010-10-27 | 2017-06-15 | Prometic Pharma Smt Ltd | Compounds and compositions for the treatment of cancer |
CN107028926A (zh) * | 2011-08-26 | 2017-08-11 | 国立大学法人大阪大学 | 糖尿病性心血管并发症的预防/治疗剂 |
KR20130023583A (ko) * | 2011-08-29 | 2013-03-08 | 아주대학교산학협력단 | 파골세포 형성 억제 효과가 있는 카프르산 및 이를 포함하는 약학적 조성물 |
US10130603B2 (en) | 2013-11-05 | 2018-11-20 | Colgate-Palmolive Company | Methods and compositions for improving kidney function |
WO2017074266A1 (en) * | 2015-10-30 | 2017-05-04 | National University Of Singapore | Androgen biosynthesis inhibitor |
CN105559071A (zh) * | 2016-01-12 | 2016-05-11 | 刘保惠 | 一种适用于肾病的特殊医学用途配方食品及其制备方法 |
JP2017214342A (ja) * | 2016-06-02 | 2017-12-07 | 日清オイリオグループ株式会社 | 排尿障害の予防用又は改善用組成物 |
CN117298092A (zh) | 2016-06-08 | 2023-12-29 | 善睿圣医药保健股份有限公司 | 具有奇数碳的脂类化合物及其作为医药组合物或者营养补充剂的用途 |
BR112019012538A2 (pt) * | 2016-12-21 | 2019-11-12 | Prometic Pharma Smt Ltd | métodos e composições para prevenir ou minimizar a transição epitelial-mesenquimal |
WO2019082912A1 (ja) * | 2017-10-27 | 2019-05-02 | 学校法人北里研究所 | 慢性腎臓病の予防又は治療剤 |
US20190240180A1 (en) * | 2018-02-08 | 2019-08-08 | Nestec Sa | Mct-based nutrition blend for providing health benefits in companion animals |
CN109602012A (zh) * | 2018-12-11 | 2019-04-12 | 李卫平 | 一种功能性低蛋白能量米及其制备方法 |
CN111184728B (zh) * | 2020-02-20 | 2023-04-04 | 上海市儿童医院 | 海藻糖在肾病综合征中的应用 |
WO2023244709A1 (en) * | 2022-06-15 | 2023-12-21 | Hill's Pet Nutrition, Inc. | Pet food compositions |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4602040A (en) | 1983-04-18 | 1986-07-22 | Warner-Lambert Company | Meclofenamic acid topical pharmaceutical composition |
US4737384A (en) * | 1985-11-01 | 1988-04-12 | Allied Corporation | Deposition of thin films using supercritical fluids |
CA2107581A1 (en) * | 1992-02-07 | 1993-08-08 | Kiyoshi Sugiyama | Side-effect alleviant |
US6689700B1 (en) * | 1999-11-02 | 2004-02-10 | University Of Massachusetts | Chemical fluid deposition method for the formation of metal and metal alloy films on patterned and unpatterned substrates |
WO2001097799A1 (en) | 2000-06-20 | 2001-12-27 | Nutrition Sciences | Medium chain fatty acids applicable as antimicrobial agents |
IL142535A0 (en) * | 2001-04-11 | 2002-03-10 | Yeda Res & Dev | Pharmaceutical compositions for the treatment of inflammation |
PL223348B1 (pl) * | 2001-04-18 | 2016-10-31 | Prometic Biosciences Inc | Zastosowanie karboksylanu |
CN1827766B (zh) * | 2001-06-28 | 2010-08-25 | 徐荣祥 | 体外细胞的培养方法 |
RU2213570C2 (ru) * | 2001-08-22 | 2003-10-10 | Санкт-Петербургская Государственная Химико-Фармацевтическая Академия | ЛЕЧЕБНО-ПРОФИЛАКТИЧЕСКОЕ СРЕДСТВО ИЗ ЛИСТЬЕВ ЛИПЫ Folia Tilia И СПОСОБ ПОЛУЧЕНИЯ ЭКСТРАКТИВНЫХ ВЕЩЕСТВ |
US7030168B2 (en) * | 2001-12-31 | 2006-04-18 | Advanced Technology Materials, Inc. | Supercritical fluid-assisted deposition of materials on semiconductor substrates |
US20040052836A1 (en) | 2002-09-13 | 2004-03-18 | Li Luk Chiu | Pharmaceutical compositions containing at least one stable liposphere having an improved shelf life |
AP2005003367A0 (en) * | 2003-02-07 | 2005-09-30 | Prometic Biosciences Inc | Medium-chain length fatty acids, glycerides and analogues as stimulators of erythropoiesis. |
CN1839111B (zh) | 2003-07-25 | 2010-04-21 | 普罗米蒂克生物科学公司 | 中链脂肪酸金属盐的制备方法 |
EP1940379A4 (en) * | 2005-09-30 | 2009-05-13 | Jackson H M Found Military Med | METHOD FOR THE TREATMENT OF HEMORRHAGIC SHOCKS AND ASSOCIATED DISEASES |
CN101374416A (zh) * | 2006-01-30 | 2009-02-25 | 环亚有限公司 | 逆转、防止、延迟或稳定软组织钙化的方法 |
-
2008
- 2008-11-03 CN CN200880113724XA patent/CN101878028A/zh active Pending
- 2008-11-03 MX MX2010004856A patent/MX338513B/es active IP Right Grant
- 2008-11-03 MY MYPI2010001861A patent/MY151439A/en unknown
- 2008-11-03 KR KR1020107012064A patent/KR101601987B1/ko active IP Right Grant
- 2008-11-03 BR BRPI0818310A patent/BRPI0818310A8/pt not_active IP Right Cessation
- 2008-11-03 US US12/740,700 patent/US9532962B2/en active Active
- 2008-11-03 NZ NZ584981A patent/NZ584981A/en not_active IP Right Cessation
- 2008-11-03 RU RU2010122302/15A patent/RU2519215C2/ru active
- 2008-11-03 DK DK08845122.4T patent/DK2299998T3/en active
- 2008-11-03 WO PCT/CA2008/001930 patent/WO2009055933A1/en active Application Filing
- 2008-11-03 CA CA2704286A patent/CA2704286C/en not_active Expired - Fee Related
- 2008-11-03 ES ES08845122.4T patent/ES2664594T3/es active Active
- 2008-11-03 NO NO08845122A patent/NO2299998T3/no unknown
- 2008-11-03 AU AU2008318196A patent/AU2008318196B2/en not_active Ceased
- 2008-11-03 JP JP2010532389A patent/JP5575655B2/ja not_active Expired - Fee Related
- 2008-11-03 EP EP08845122.4A patent/EP2299998B1/en active Active
- 2008-11-03 PT PT88451224T patent/PT2299998T/pt unknown
-
2010
- 2010-04-26 IL IL205362A patent/IL205362A/en active IP Right Grant
- 2010-04-30 ZA ZA2010/03030A patent/ZA201003030B/en unknown
Also Published As
Publication number | Publication date |
---|---|
US9532962B2 (en) | 2017-01-03 |
EP2299998A1 (en) | 2011-03-30 |
AU2008318196A1 (en) | 2009-05-07 |
AU2008318196B2 (en) | 2014-04-10 |
EP2299998B1 (en) | 2018-01-03 |
CA2704286A1 (en) | 2009-05-07 |
KR101601987B1 (ko) | 2016-03-09 |
MY151439A (en) | 2014-05-30 |
CA2704286C (en) | 2016-08-23 |
JP5575655B2 (ja) | 2014-08-20 |
ES2664594T3 (es) | 2018-04-20 |
CN101878028A (zh) | 2010-11-03 |
BRPI0818310A2 (pt) | 2017-10-10 |
PT2299998T (pt) | 2018-04-02 |
DK2299998T3 (en) | 2018-03-26 |
EP2299998A4 (en) | 2011-03-30 |
NZ584981A (en) | 2012-05-25 |
IL205362A0 (en) | 2010-12-30 |
NO2299998T3 (es) | 2018-06-02 |
BRPI0818310A8 (pt) | 2017-12-26 |
MX2010004856A (es) | 2010-06-30 |
IL205362A (en) | 2015-01-29 |
RU2519215C2 (ru) | 2014-06-10 |
RU2010122302A (ru) | 2011-12-10 |
ZA201003030B (en) | 2011-02-23 |
US20100286269A1 (en) | 2010-11-11 |
WO2009055933A1 (en) | 2009-05-07 |
KR20100106958A (ko) | 2010-10-04 |
JP2011502174A (ja) | 2011-01-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX338513B (es) | Acidos grasos de longitud de cadena mediana y gliceridos como agentes de nefroprotección. | |
WO2007073486A3 (en) | Methods and compositions for delivering active agents with enhanced pharmacological properties | |
NZ591057A (en) | Complement antagonists and uses thereof | |
EP2671584A3 (en) | Compositions and methods for treating disorders associated with salt or fluid retention | |
CL2012002317A1 (es) | Compuestos derivados de tienopirimidinas, inhibitores de quinasas mnk1/mnk2; composicion farmaceutica; y su uso para elt ratamiento o profilaxis de enfermedades metabolicas, tales como diabetes, daño renal, cancer, enfermedades inflamatorias, entre otras. | |
AU2016219611A1 (en) | Compositions comprising mixtures of semifluorinated alkanes | |
WO2013158680A3 (en) | Compositions and methods comprising celecoxib or related compounds and dextromethorphan | |
WO2009109927A3 (en) | Glp-1 receptor agonists and related active pharmaceutical ingredients for treatment of cancer | |
MX353466B (es) | Corticosteroides para el tratamiento de dolor de articulaciones. | |
PH12015502275A1 (en) | Therapuetic uses of empagliflozin | |
BR112012012028A2 (pt) | dispositivo telescópico | |
MX2011008450A (es) | Agonistas y antagonistas del receptor s1p5, y metodos de uso de los mismos. | |
MX2020010004A (es) | Composicion farmaceutica que comprende empagliflozina, metodos para tratamiento y sus usos. | |
WO2009063222A3 (en) | Solid compositions | |
JP2010222367A5 (es) | ||
WO2007138466A3 (en) | Pharmaceutical compositions comprising meloxicam and tramadol combination | |
MY156275A (en) | Compositions comprising tramadol and celecoxib in the treatment of pain | |
CL2012000333A1 (es) | Antagonista del receptor de la endotelina útil en la prevención o el tratamiento de metástasis cerebral en combinación con un agente de quimioterapia citotóxico, radioterapia o ambos; su uso para inhibir protección mediada por astrocito de una célula cerebral metastasica de una muerte celular inducida por quimioterapia citotóxica; y su uso para tratar un tumor cerebral metastásico. | |
CL2012002437A1 (es) | Uso de antiinflamatorio no esteroide (aine) o una sal farmacologicamente aceptable del mismo para preparar un medicamento util para el tratamiento de enfermedades renales cronicas en gatos. | |
WO2012053013A3 (en) | Pharmaceutical compositions of anti-acne agents | |
WO2015168488A3 (en) | Islet amyloid polypeptides with improved solubility | |
EP2371368A3 (en) | Compositions and methods for treatment of inflammation and hyperkeratotic lesions | |
MX2019003039A (es) | Forma de dosificacion de alivio prolongado. | |
ZA201404068B (en) | The use of silver(i) complexes as active pharmaceutical ingredients (api's) iincluding anticancer agents | |
MY164112A (en) | A combination composition comprising ibuprofen and paracetamol |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |